Comparisons › JNJ / ABBV
Johnson & Johnson vs AbbVie: comparing JNJ and ABBV stock
12-month growth, from 100━ JNJ +48.1% ━ ABBV +35.2%
| Metric | JNJ | ABBV |
|---|---|---|
| Price, $ | 272.32 | 288.24 |
| Year to date | +32.3% ● | +28.2% |
| 12 months | +48.1% ● | +35.2% |
| From 52-week high | −3.4% ● | −4.8% |
| vs 200-day average | +9.9% | +21.1% ● |
| P/E | 25.6 | 22.5 |
| Dividend yield | 1.96% | 2.47% ● |
| Revenue growth, YoY | +7.8% | +10.7% ● |
| Operating income growth | +7.7% | +18.8% ● |
| Operating margin | 26.6% | 36.6% ● |
| Gross margin | 67.8% | 73.7% ● |
| Market cap | $655.6B | $509.5B |
| Next earnings | Jan 26, 2027 | Feb 3, 2027 |
● — whose figure is higher, not which is better. Data as of Nov 5, 2026.
Ratings and a detailed chart for each are in the terminal.
Open the terminalFAQ
Which is better to buy: Johnson & Johnson or AbbVie?
We do not advise what to buy. By the numbers: Johnson & Johnson rose more over the year (+48.1%); Johnson & Johnson is closer to its 52-week high; AbbVie has the higher operating margin; AbbVie is growing revenue faster; AbbVie has the lower P/E. How to weigh such signs is covered in «How to analyse a stock».
Can I buy both?
Yes. Many hold several companies in one industry to avoid depending on one. A broad index fund often already holds the largest US companies.
When do they report?
Johnson & Johnson — Jan 26, 2027; AbbVie — Feb 3, 2027.